[Mitral valve replacement for cabergoline-related severe mitral regurgitation].
An 82-year-old man was referred to our hospital because of progressive heart failure. He had Parkinson's disease and had been treated with cabergoline during the preceding 4 years and 8 months. Echocardiography revealed severe mitral regurgitation through retracted mitral leaflets with incomplete coaptation. Heart failure persisted despite pharmacologic therapy, so the mitral valve was surgically replaced with a biological valve. Histologic analysis showed fibrous thickened mitral chordae with myxoid degeneration. These characteristics of the mitral valve of our patient are similar to the valvular heart disease described with the use of cabergoline. Clinicians must be care of valvular heart disease whenever they treat Parkinson's disease patients with cabergoline.
Hanada
Tomoki
T
Unit of Cardiovascular and Chest Surgery, Department of Surgery, Faculty of Medicine, Shimane University, Izumo, Japan.
Shimizu
K
K
Murakami
R
R
Ota
T
T
Okada
S
S
Inoue
S
S
Hiroe
K
K
Higaki
Y
Y
Oda
T
T
D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001705:Bioprosthesis; D000077465:Cabergoline; D002815:Chordae Tendineae / Q000473:pathology; D004452:Echocardiography; D004873:Ergolines / Q000009:adverse effects*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery*; D010300:Parkinson Disease / Q000188:drug therapy
D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline